Home › Polycystic Ovary Syndrome › NCT07871149
PMOS in OSA Pilot Study
Recruiting
Metabolic Changes in PMOS Patients With Obstructive Sleep Apnea (OSA) Pilot Study
Who can join
Ages 18 to 40 · Women
Full eligibility criteria
Inclusion Criteria: * Women 18-40 years old * PMOS diagnosis * Sleep Apnea (AHI\>5) diagnosed by home sleep test (WatchPAT One) * BMI\< 50.0 Exclusion Criteria: * Regular adherent CPAP use per clinical guidelines * Any history of bleeding disorders * Current use of anti-coagulant medication * Hemoglobin \<11.6 g/dL * Currently pregnant, pregnant within the last year, or gave birth within the last year * Any underlying disease likely to limit life span and/or increase risk of interventions including cardiovascular disease (e.g. unstable angina, heart failure requiring hospitalization in the past 6 months, significant heart block or arrhythmias, NYHA Class\>2), pulmonary disease with dependence on oxygen or daily use of bronchodilators, cancer requiring treatment in the past 5 years unless the prognosis is considered good, active or chronic infection, thyroid disease and other endocrine disorders (e.g. Cushing syndrome, acromegaly), hepatitis or other chronic gastrointestinal disease (pancreatitis, inflammatory bowel disease), renal disease, significant anemia, recent surgery or significant abdominal surgery, major psychiatric or any eating disorder, acute coronary syndrome or stroke in the past 6 months
About the study
The goal of this study is to obtain pilot data investigating the effects of sleep apnea on mitochondrial function and cellular metabolism in Polyendocrine Metabolic Ovarian Syndrome (PMOS) patients.
What is being tested
- Continuous Positive Airway Pressure (CPAP) (device)
Sponsor: University of Chicago · Participants: 10 · Started: 2026-10
Contact the study team
- Bonnie Olivia Hughes · Phone: 773-834-7809
Official record on ClinicalTrials.gov — NCT07871149
Locations in the U.S.
| Illinois | University of Chicago, Chicago |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.